In addition, the trial included a cohort of patients with high-level METamp, EGFR/ALK wild-type NSCLC without METex14 skipping, in which tepotinib demonstrated clinically meaningful activity and induced durable responses (16). This evidence concerns the gene EGFR and non-small cell lung carcinoma.